Brainstorm Cell Therapeutics Stock Investor Sentiment

BCLI Stock  USD 1.71  0.03  1.72%   
Under 62% of Brainstorm Cell's investor base is looking to short. The analysis of the overall investor sentiment regarding Brainstorm Cell Therapeutics suggests that many traders are alarmed. Brainstorm Cell's investing sentiment shows overall attitude of investors towards Brainstorm Cell Therapeutics.
  

Brainstorm Cell Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Brainstorm Cell can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over two months ago at www.macroaxis.com         
Acquisition by Chaim Lebovits of 22000 shares of Brainstorm Cell at 0.228 subject to Rule 16b-3
Macroaxis News
over two months ago at thelincolnianonline.com         
Brainstorm Cell Therapeutics Research Coverage Started at StockNews.com
news
over two months ago at news.google.com         
BrainStorm announces reverse stock split - Investing.com
Google News at Macroaxis
over two months ago at finance.yahoo.com         
BrainStorm Cell Therapeutics Announces Presentations on NurOwn at 2024 Annual NEALS Meeting
Yahoo News
over two months ago at www.macroaxis.com         
Acquisition by Uri Yablonka of 13333 shares of Brainstorm Cell at 0.75 subject to Rule 16b-3
Macroaxis News
over three months ago at news.google.com         
SEC Form S-3 filed by Brainstorm Cell Therapeutics Inc. - Quantisnow
Google News at Macroaxis
over three months ago at finance.yahoo.com         
BCLI SPA in Place for Phase 3b Trial of NurOwn in ALS
Yahoo News
over three months ago at gurufocus.com         
Brainstorm Cell Therapeutics Inc Q2 2024 Earnings Call Transcript Highlights ...
Gurufocus Stories at Macroaxis
over three months ago at investing.com         
Earnings call Brainstorm Cell Therapeutics outlines Phase 3b trial plans
Investing News at Macroaxis
over three months ago at insidermonkey.com         
Brainstorm Cell Therapeutics Inc. Q2 2024 Earnings Call Transcript
insidermonkey News
over three months ago at finance.yahoo.com         
BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate ...
Yahoo News
over three months ago at investorplace.com         
BCLI Stock Earnings Brainstorm Cell Misses EPS for Q2 2024
sbwire news
over three months ago at finance.yahoo.com         
BrainStorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate Update
Yahoo News
over three months ago at news.google.com         
Brainstorm Cell Therapeutics Earns Hold Rating from Analysts at StockNews.com - Defense World
Google News at Macroaxis
over three months ago at finance.yahoo.com         
BCLI Update - Progress Supports Our 10x Plus Value Range Potential
Yahoo News
Far too much social signal, news, headlines, and media speculation about Brainstorm Cell that are available to investors today. That information is available publicly through Brainstorm media outlets and privately through word of mouth or via Brainstorm internal channels. However, regardless of the origin, that massive amount of Brainstorm data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Brainstorm Cell news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Brainstorm Cell relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Brainstorm Cell's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Brainstorm Cell alpha.

Brainstorm Cell Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Uri Yablonka of 13333 shares of Brainstorm Cell at 0.75 subject to Rule 16b-3
09/16/2024
2
BrainStorm Cell Therapeutics Announces Presentations on NurOwn at 2024 Annual NEALS Meeting
09/24/2024
3
Acquisition by Chaim Lebovits of 22000 shares of Brainstorm Cell at 0.228 subject to Rule 16b-3
09/30/2024
4
Acquisition by Chaim Lebovits of 1836 shares of Brainstorm Cell at 3.4272 subject to Rule 16b-3
10/01/2024
5
BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn Trial at the 2024 Maxim Healthcare Virtual Summit
10/07/2024
6
Disposition of 9600 shares by Patlis Alla of Brainstorm Cell at 9.51 subject to Rule 16b-3
10/10/2024
7
Acquisition by Chaim Lebovits of 135000 shares of Brainstorm Cell at 0.3753 subject to Rule 16b-3
10/11/2024
8
BrainStorm Cell Therapeutics regains compliance with Nasdaq
10/30/2024
9
Acquisition by Arbel Irit of 25333 shares of Brainstorm Cell at 0.75 subject to Rule 16b-3
11/12/2024
10
BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Yahoo Canada Finance
11/14/2024
11
BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis on December 11, 2024
12/02/2024

Complementary Tools for Brainstorm Stock analysis

When running Brainstorm Cell's price analysis, check to measure Brainstorm Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brainstorm Cell is operating at the current time. Most of Brainstorm Cell's value examination focuses on studying past and present price action to predict the probability of Brainstorm Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Brainstorm Cell's price. Additionally, you may evaluate how the addition of Brainstorm Cell to your portfolios can decrease your overall portfolio volatility.
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing